Ipca gains on 'outperform' rating by Credit Suisse

Reuters Market Eye - Shares in Ipca Laboratories Ltd rise after Credit Suisse initiated coverage on the stock with an "outperform" rating, traders say.

Credit Suisse cites Ipca's sales and earnings growth potential, increasing free cash flow and reduced dependence on lower-margin drug sales.

The investment bank also cites Ipca's market leadership in the rheumatoid arthritis segment in India.

Ipca shares were up 4.4 percent at 3.07 p.m.

(Reporting by Indulal PM)